HIV coreceptor usage and drug treatment

Journal of Theoretical Biology

Volumn 217, Issue 4, 2002, Pages 443-457

  Regoes, Roland R ^a   Bonhoeffer, Sebastian ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BLOCKING AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4;

HUMAN IMMUNODEFICIENCY VIRUS;

ARTICLE; CELL TYPE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; MATHEMATICAL MODEL; MEMORY CELL; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BINDING; RISK BENEFIT ANALYSIS; T LYMPHOCYTE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0036399460     PISSN: 00225193     EISSN: None     Source Type: Journal    
DOI: 10.1006/jtbi.2002.3049     Document Type: Article

References (63)

1. Anderson, R. M. & May, R. M. (1981). The population dynamics of microparasites and their invertebrate hosts. Philos. Trans. R. Soc. B 291, 451-524.
2. Anderson, R. M. & May, R. M. (1991). Infectious Diseases of Humans. Oxford: Oxford University Press.
3. Arakaki, R., Tamamura, H., Premanathan, M., Kan-bara, K., Ramanan, S., Mochizuki, K., Baba, M., Fujii, N. & Nakashima, H. (1999). T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J. Virol. 73, 1719-1723.
4. Asjo, B., Albert, J., Karlsson, A., Morfeldtmanson, L., Biberfeld, G., Lidman, K. & Fenyo, E. M. (1986).Replicative capacity of human-immunodeficiency-virus from patien its with varying severity of HIV-infection. Lancet 2, 660-662.
5. Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiraishi, M., Aramaki, Y., Okonogi, K., Ogawa, Y., Meguro, K. & Fujino, M. (1999). A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl Acad. Sci. U.S.A., 96, 5698-5703.
6. Berger, E. A., Doms, R. W., Fenyo, E. M., Korber, B. T. M., Littman, D. R., Moore, J. P., Sattentau, Q. J., Schuitemaker, H., Sodroski, J. & Weiss, R. A. (1998). A new classification for HIV-1. Nature 391, 240.
7. Bjorndal, A., Deng, H. K., Jansson, M., Fiore, J. R., Colognesi, C., Karlsson, A., Albert, J., Scarlatti, G., Littman, D. R. & Fenyo, E. M. (1997). Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71, 7478-7487.
8. Blaak, H., van't Wout, A. B., Brouwer, M., Hooibrink, B., Hovenkamp, E. & Schuitemaker, H. (2000). In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. Proc. Natl Acad. Sci. U.S.A, 97, 1269-1274.
9. Bleul, C. C., Wu, L., Hoxie, J. A., Springer, T. A. & Mackay, C. R. (1997). The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl Acad. Sci. U.S.A. 94, 1925-1930.
10. Bonhoeffer, S., Coffin, J. M. & Nowak, M. A. (1997a). HIV-drug therapy and virus load. J. Virol. 71, 3725-3728.
11. Bonhoeffer, S., May, R. M., Shaw, G. M. & Nowak, M. A. (1997b). Virus dynamics and drug therapy. Proc. Natl Acad. Sci. U.S.A. 94, 6971-6976.
12. Bonhoeffer, S. & Nowak, M. A. (1997). Pre-existence and the emergence of drug resistance in HIV-infection. Proc. R. Soc. Lond. B 264, 631-637.
13. Bremermann, H. J. & Thieme, H. R. (1989). A competitive-exclusion principle for pathogen virulence. J. Math. Biol. 27, 179-190.
14. Callaway, D. S., Ribeiro, R. M. & Nowak, M. A. (1999). Virus phenotype switching and disease progression in HIV-1 infection. Proc. R. Soc. Lond. B 266, 2523-2530.
15. Cheng-Mayer, C., Quiroga, M., Tung, J. W., Dina, D. & Levy, J. A. (1990). Viral determinants of human-immunodeficiency-virus type-1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J. Virol. 64, 4390-4398.
16. Chou, C. S., Ramilo, O. & Vitetta, E. S. (1997). Highly purified CD25(-) resting T cells cannot be infected de novo with HIV-1. Proc. Natl Acad. Sci. U.S.A. 94, 1361-1365.
17. Connor, R. I., Mohri, H., Cao, Y. & Ho, D. D. (1993). Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J. Virol. 67, 1772-1777.
18. Cornelissen, M., Mulder-Kampinga, G., Veenstra, J., Zorgdrager, F., Kuiken, C., Hartman, S., Dekker, J., van der Hoek, L., Sol, C., Coutinho, R. & Goudsmit, J. (1995). Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. J. Virol. 69, 1810-1818.
19. 0 in models for infectious-diseases in heterogeneous populations. J. Math. Biol. 28, 365-382.
20. Dietz, K. (1975). Transmission and control of arbovirus diseases. In: Epidemiology (Ludwig, D. & Cooke, K. L., eds), pp. 104-121, Philadelphia, PA: Society for Industrial and Applied Mathematics.
21. Dietz, K. (1976). The incidence of infectious diseases under the influence of seasonal fluctuations. In: Mathematical Models in Medicine (Berger, J., Buhler, W., Repges, R. & Tautu, P., eds), pp. 1-15. Berlin: Springer-Verlag.
22. Eckstein, D. A., Penn, M. L., Korin, Y. D., Scripture Adams, D. D., Zack, J. A., Kreisberg, J. F., Roederer, M., Sherman, M. P., Chin, P. S. & Goldsmith, M. A. (2001). HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity 15, 671-682.
23. Este, J., Cabrera, C., Blanco, J., Gutierrez, A., Bridger, G., Henson, G., Clotet, B., Schols, D. & De Clercq, E. (1999). Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and blockade of CXCR4. J. Virol. 73, 5577-5585.
24. Fenyo, E. M., Morfeldt-Manson, L., Chiodi, F., Lind, B., von Gegerfelt, A., Albert, J., Olausson, E. & Asjo, B. (1988). Distinct replicative and cytopathic characteristics of human immunodeficiency isolates. J. Virol. 62, 4414-4419.
25. Frost, S. D. W. & McLean, A. R. (1994). Quasi-species dynamics and the emergence of drug-resistance during zidovudine therapy of HIV-infection. AIDS 8, 323-332.
26. Helbert, M. R., Walter, J., Lage, J. & Beverley, P. C. L. (1997). HIV infection of CD45RA(+) and CD45RO(+) CD4(+) T cells. Clin. Exp. Immunol. 107, 300-305.
27. Karlsson, A., Parsmyr, K., Sandstrom, E., Fenyo, E. M. & Albert, J. (1994). MT-2 cell tropism as prognostic marker for disease progression in human-immunodeficiency-virus type-1 infection. J. Microbiol. 2, 364-370.
28. Katzenstein, D. A., Hammer, S. M., Hughes, M. D., Gundacker, H., Jackson, J. B., Fiscus, S., Rasheed, S., Elbeik, T., Reichman, R., Japour, A., Merigan, T. C. & Hirsch, M. S. (1996). The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N. Engl. J. Med. 335, 1091-1098.
29. Keet, I. P. M., Krijnen, P., Koot, M., Lange, J. M. A., Miedema, F., Goudsmit, J. & Coutinho, R. A. (1993). Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 7, 51-57.
30. Kepler, T. B. & Perelson, A. S. (1998). Drug concentration heterogeneity facilitates the evolution of drug resistance. Proc. Natl Acad. Sci. U.S.A. 95, 11514-11519.
31. Koot, M., Keet, I. P. M., Vos, A. H. V., Degoede, R. E. Y., Roos, M. T. L., Coutinho, R. A., Miedema, F., Schellekens, P. T. A. & Tersmette, M. (1993a). Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann. Intern. Med. 118, 681-688.
32. Koot, M., Schellekens, P. T. A., Mulder, J. W., Lange, J. M. A., Roos, M. T. L., Coutinho, R. A., Tersmette, M. & Miedema, F. (1993b). Viral phenotype and T-cell reactivity in human-immunodeficiency-virus type-1-infected asymptomatic men treated with zidovudine. J. Infect. Dis. 168, 733-736.
33. Lathey, J. L., Pratt, R. D. & Spector, S. A. (1997). Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1 [letter; comment]. J. Infect. Dis. 175, 231-232.
34. Lee, B., Sharron, M., Montaner, L. J., Weissman, D. & Doms, R. W. (1999). Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc. Natl Acad. Sci. U.S.A. 96, 5215-5220.
35. Maeda, Y., Foda, M., Matsushita, S. & Harada, S. (2000). Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1α. J. Virol. 74, 1787-1793.
36. May, R. M. & Anderson, R. M. (1983). Epidemiology and genetics in the coevolution of parasites and hosts. Proc. R. Soc. Lond. B 219, 281-313.
37. Mosier, D. E., Picchio, G. R., Gulizia, R. J., Sabbe, R., Poignard, P., Picard, L., Offord, R. E., Thompson, D. A. & Wilken, J. (1999). Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 73, 3544-3550.
38. Murakami, T., Nakajima, T., Koyanagi, N., Tachibana, K., Fujii, N., Tamamura, H., Yoshida, N., Waki, M., Matsumoto, A., Yoshie, O., Kishimoto, T., Yamamoto, N. & Nagasawa, T. (1997). A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med. 186, 1389-1393.
39. Nowak, M. A., Bonhoeffer, S., Shaw, G. M. & May, R. M. (1997). Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. J. theor. Biol. 184, 205-219.
40. O'Brien, W. A., Sumnersmith, M., Mao, S. H., Sadeghi, S., Zhao, J. Q. & Chen, I. Y. (1996). Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J. Virol. 70, 2825-2831.
41. Ostrowski, M. A., Chun, T. W., Justement, S. J., Motola, I., Spinelli, M. A., Adelsberger, J., Ehler, L. A., Mizell, S. B., Hallahan, C. W. & Fauci, A. S. (1999). Both memory and CD45RA(+)/CD62L(+) naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals. J. Virol. 73, 6430-6435.
42. Ostrowski, M. A., Justement, S. J., Catanzaro, A., Hallahan, C. A., Ehler, L. A., Mizell, S. B., Kumar, P. N., Mican, J. A., Chun, T. W. & Fauci, A. S. (1998). Expression of chemokine receptors CXCR4 and CCR5 in HIV-1- infected and uninfected individuals. J. Immunol. 161, 3195-3201.
43. Regoes, R. R., Bonhoeffer, S. & Nowak, M. A. (2000). Evolution of virulence in a heterogeneous host population. Evolution 54, 64-71.
44. Ribeiro, R. M., Bonhoeffer, S. & Nowak, M. A. (1998). The frequency of drug resistant mutants before therapy. AIDS 12, 461-465.
45. Roederer, M., Raju, P. A., Mitra, D. K., Herzenberg, L. A. & Herzenberg, L. A. (1997). HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28. J. Clin. Invest. 99, 1555-1564.
46. Schnittman, S. M., Lane, H. C., Greenhouse, J., Justement, J. S., Baseler, M. & Fauci, A. S. (1990). Preferential infection of CD4+ memory T-cells by human- immunodeficiency-virus type-1-evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc. Natl Acad. Sci. U.S.A. 87, 6058-6062.
47. Schols, D., Este, J. A., Cabrera, C. & De Clercq, E. (1998). T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1α contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J. Virol. 72, 4032-4037.
48. Schols, D., Este, J. A., Henson, G. & de Clercq, E. (1997). Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res. 35, 147-156.
49. Schuitemaker, H., Koot, M., Kootstra, M. A., Dercksen, M. W., de Gode, R. E. Y., van Steenwijk, R. P., Lange, J. M. A., Schattenkerk, J. K. M. E., Miedema, F. & Tersmette, M. (1992). Biological phenotype of human immunodeficiency virus type-1 clones at different stages of infection-progression of disease is associated with a shift from monocytotropic to T-cell tropic virus population. J. Virol. 66, 1354-1360.
50. Spijkerman, I., De Wolf, F., Langendam, M., Schuitemaker, H. & Coutinho, R. (1998). Emergence of syncytium-inducing human immunodeficiency virus type 1 variants coincides with a transient increase in viral RNA level and is an independent predictor for progression to AIDS. J. Infect. Dis. 178, 397-403.
51. Spina, C. A., Prince, H. E. & Richman, D. D. (1997). Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. J. Clin. Invest. 99, 1774-1785.
52. Strizki, J. M., Xu, S., Wagner, N. E., Wojcik, L., Liu, J., Hou, Y., Endres, M., Palani, A., Shapiro, S., Clader, J. W., Greenlee, W. J., Tagat, J. R., Mccombie, S., Cox, K., Fawzi, A. B., Chou, C. C., Pugliese-Sivo, C., Davies, L., Moreno, M. E., Ho, D. D., Trkola, A., Stoddart, C. A., Moore, J. P., Reyes, G. R. & Baroudy, B. M. (2001). SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl Acad. Sci. U.S.A. 98, 12718-12723.
53. Tamamura, H., Xu, Y. O., Hattori, T., Zhang, X. Y., Arakaki, R., Kanbara, K., Omagari, A., Otaka, A., Ibuka, T., Yamamoto, N., Nakashima, H. & Fujii, N. (1998). A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem. Biophys. Res. Commun. 253, 877-882.
54. Tersmette, M., de Goede, R. E. Y., Al, B. J. M. Winkel, I. N., Gruters, R. A., Cuypers, H. T., Huisman, H. G. & Miedem, F. (1988). Differential syncytium-inducing capacity of human immunodeficiency virus isolates-frequent detection of syncytium-inducing isolates in patients with aquired immunodeficiency syndrome (AIDS) and AIDS related complex. J. Virol. 62, 2026-2032.
55. Tersmette, M., Gruters, R. A., Dewolf, F., Degoede, R. E. Y., Lange, J. M. A., Schellekens, P. T. A., Goudsmit, J., Huisman, H. G. & Miedema, F. (1989a). Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome-studies on sequential HIV isolates. J. Virol. 63, 2118-2125.
56. Tersmette, M., Lange, J. M. A., Degoede, R. E. Y., Dewolf, F., Eeftinkschattenkerk, J. K. M., Schellekens, P. T. A., Coutinho, R. A., Huisman, J. G., Goudsmit, J. & Miedema, F. (1989b). Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1, 983-985.
57. Trkola, A., Ketas, T. J., Nagashima, K. A., Zhao, L., Cilliers, T., Morris, L., Moore, J. P., Maddon, P. J. & Olson, W. C. (2001). Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75, 579-588.
58. Trkola, A., Kuhmann, S. E., Strizki, J. M., Maxwell, E., Ketas, T., Morgan, T., Pugach, P., Xu, S., Wojcik, L., Tagat, J., Palani, A., Shapiro, S., Clader, J. W., Mccombie, S., Reyes, G. R., Baroudy, B. M. & Moore, J. P. (2002). HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl Acad. Sci. U.S.A. 99, 395-400.
59. Wodarz, D. & Krakauer, D. C. (2000). Defining CTL-induced pathology: implications for HIV. Virology 274, 94-104.
60. Wodarz, D., Lloyd, A. L., Jansen, V. A. & Nowak, M. A. (1998). Dynamics of macrophage and T cell infection by HIV. J. theor. Biol. 196, 101-113.
61. Wodarz, D. & Nowak, M. A. (1998). The effect of different immune responses on the evolution of virulent CXCR4-tropic HIV. Proc. R. Soc. Lond. B 265, 2149-2158.
62. Xiao, L. H., Rudolph, D. L., Owen, S. M., Spira, T. J. & Lal, R. B. (1998). Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS 12, F137-F143.
63. Zhang, Z. Q., Schuler, T., Zupancic, M., Wietgrefe, S., Staskus, K. A., Reimann, K. A., Reinhart, T. A., Rogan, M., Cavert, W., Miller, C. J., Veazey, R. S., Notermans, D., Little, S., Danner, S. A., Richman, D. D., Havlir, D., Wong, J., Jordan, H. L., Schacker, T. W., Racz, P., Tenner Racz, K., Letvin, N. L., Wolinsky, S. & Haase, A. T. (1999). Sexual transmission and propagation of SIV and HIV in resting and activated CD4(+) T cells. Science 286, 1353-1357.